文献速递神经技术与安全MRPETCT

CRISPR/Cas9工程化三融合报告基因成像系统用于监测缺血性卒中移植神经祖细胞

CRISPR/Cas9-Engineered Triple-Fusion Reporter Gene Imaging System for Monitoring Transplanted Neural Progenitor Cells in Ischemic Stroke.
PubMed 文献 · Radiology · 2025-01-01

研究在大鼠缺血性卒中模型中,采用CRISPR/Cas9工程化三融合报告基因系统结合无创腺苷激动剂胶束探针递送策略,对移植人神经祖细胞进行长期活体监测。结果显示移植细胞在缺血脑内增殖、迁移并成熟,移植组葡萄糖摄取增高且神经功能缺损减轻。

要点

  • 三融合报告基因联合腺苷激动剂胶束探针可实现移植人神经祖细胞的活体示踪。
  • 移植细胞在缺血大鼠脑内增殖并迁移成熟,第8周微管相关蛋白2阳性比例达94.08%±3.02。
  • 移植组较载体组缺血脑葡萄糖摄取增高、神经功能评分改善。

核心结论

  • CRISPR/Cas9工程化三融合报告基因成像系统联合无创腺苷激动剂胶束策略,可在大鼠缺血性卒中模型中活体监测移植人神经祖细胞。

研究设计与样本

  • 研究论文;2021年1月至2025年5月纳入60只2月龄雄性大鼠,37只卒中大鼠接受三融合人神经祖细胞或载体(培养基)移植,于移植后第1、2、4、8周行MRI、生物发光成像、PET/CT及神经功能评估;组间比较采用t检验、单因素方差分析、线性回归和线性混合效应模型。

诊断标准与关键数值

  • 三融合人神经祖细胞在缺血大鼠脑内增殖:第8周 vs 第1周,生物发光成像 P < .001,PET P = .02。
  • 微管相关蛋白2阳性三融合人神经祖细胞比例:第8周 94.08% ± 3.02 vs 第4周 85.47% ± 6.54(P = .04)。
  • 双皮质素阳性三融合人神经祖细胞比例:第4周 83.90% ± 2.84 vs 第2周 59.74% ± 0.55(P = .02)。
  • 缺血脑氟18氟代脱氧葡萄糖摄取:第4周三融合人神经祖细胞组 0.58 ± 0.04 vs 载体组 0.37 ± 0.05(P = .008);第8周 0.52 ± 0.06 vs 0.29 ± 0.02(P = .01)。
  • 神经功能评分:第8周三融合人神经祖细胞组 9.6 ± 0.25 vs 载体组 7.6 ± 0.3(P = .003)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Background Neural progenitor cell therapy holds great potential for repairing brain damage induced by ischemic stroke, and molecular imaging plays a crucial role in evaluating the therapeutic efficacy of neural progenitor cell transplantation. However, the presence of the blood-brain barrier significantly limits the effectiveness of such imaging methods. Purpose To enable long-term monitoring of transplanted human neural progenitor cells (hNPCs) in a rat model of ischemic stroke by combining a clustered regularly interspaced short palindromic repeats/CRISPR-associated nuclease 9 (CRISPR/Cas9)-engineered triple-fusion (TF) reporter gene system with a noninvasive adenosine agonistic micelle (AM)-based probe delivery strategy. Materials and Methods Between January 2021 and May 2025, 60 male rats that were 2 months old were included. Thirty-seven rats with stroke were administered either TF human NPCs (hNPCs) or vehicle (culture media) and underwent MRI, bioluminescence imaging, PET/CT, and neurologic assessments at weeks 1, 2, 4, and 8 after transplantation. Comparisons between groups were determined by t tests, one-way analysis of variance, linear regression, and linear mixed-effects model. Results TF-hNPCs proliferated within the ischemic rat brain (week 8 vs week 1, bioluminescence imaging and PET: P < .001 and P = .02, respectively) and exhibited progressive migration and maturation by 8 weeks after transplantation (proportion of microtubule-associated protein 2-positive TF-hNPCs at week 8 vs week 4: 94.08% ± 3.02 vs 85.47% ± 6.54, respectively [P = .04]; proportion of doublecortin-positive TF-hNPCs at week 4 vs week 2: 83.90% ± 2.84 vs 59.74% ± 0.55, respectively [P = .02]). Moreover, TF-hNPC transplantation increased glucose (fluorine 18 fluorodeoxyglucose) uptake in the ischemic brain (TF-hNPCs vs vehicle at week 4, 0.58 ± 0.04 vs 0.37 ± 0.05, respectively [P = .008]; TF-hNPCs vs vehicle at week 8, 0.52 ± 0.06 vs 0.29 ± 0.02, respectively [P = .01]) and attenuated neurologic deficits compared with the vehicle group (neurologic score, TF-hNPCs vs vehicle at week 8: 9.6 ± 0.25 vs 7.6 ± 0.3, respectively; P = .003). Conclusion A CRISPR/Cas9-engineered TF reporter gene imaging system combined with a noninvasive AM-based approach enabled in vivo monitoring of transplanted human NPCs in a rat model of ischemic stroke. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Chapelin in this issue.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Li X, Zhong Y, Jin C, et al. CRISPR/Cas9-Engineered Triple-Fusion Reporter Gene Imaging System for Monitoring Transplanted Neural Progenitor Cells in Ischemic Stroke. Radiology. 2025. PMID: 40891977. doi:10.1148/radiol.250305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。